<DOC>
	<DOCNO>NCT01522742</DOCNO>
	<brief_summary>The main aim study determine whether : ) psoriasis patient without arthritis cardiovascular inflammation healthy subject b ) 3 month etanercept ( enbrel ) therapy ( prescribed psoriasis patient without arthritis treat clinician ) decrease cardiovascular inflammation .</brief_summary>
	<brief_title>Monitoring Modifying Atherosclerosis Psoriasis Patients Study</brief_title>
	<detailed_description>Psoriasis common disease characterize skin lesion systemic inflammation without arthritis . Patients psoriasis high risk cardiovascular disease healthy subject , may relate part inflammatory nature disease . This study intend help provide explanation increase cardiovascular disease risk psoriasis ass whether risk reduce biologic anti-inflammatory therapy prescribe resolve skin lesion arthritis .</detailed_description>
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Atherosclerosis</mesh_term>
	<mesh_term>Etanercept</mesh_term>
	<criteria>FOR PSORIASIS PATIENTS men woman age 1880 moderatetosevere psoriasis ( without arthritis ) newly initiate biologic therapy etanercept ( enbrel ) 50 mg twice weekly pregnancy breastfeed woman childbearing potential refusing practice abstinence use reliable barrier form birth control include condom , IUD , diaphragm history acute coronary syndrome coronary artery stenting surgery , significant autoimmune/inflammatory disease psoriasis relate psoriatic condition previous therapy psoriasis biologic agent within past 4 month new initiation statin antihyperglycemic agent within past 3 month screen hemoglobin &lt; 11 condition would make MDCT coronary angiography/ cardiac FDGPET protocol unsafe unfeasible include : significant renal dysfunction eGFR CockcroftGault equation &lt; 60 ml/min , contrast dye allergy , contraindication betablockers ( e.g . severe asthma , hypotension , heart block ) , contraindication nitroglycerin ( uninterruptable administration phosphodiesterase inhibitor ) , body weight great 320 lb ( PET scanner table limitation ) report subject significant radiation exposure course year prior enrollment ; significant exposure define : 2 myocardial perfusion study within past 12 month 2 CT angiogram within past 12 month concurrent enrollment clinical trial judge investigator introduce concern safety confound FOR HEALTHY CONTROL SUBJECTS men woman age 1880 without psoriasis pregnancy breastfeed woman childbearing potential refusing practice abstinence use reliable barrier form birth control include condom , IUD , diaphragm history acute coronary syndrome coronary artery stenting surgery , significant autoimmune/inflammatory disease screen hemoglobin &lt; 11 condition would make MDCT coronary angiography/ cardiac FDGPET protocol unsafe unfeasible include : significant renal dysfunction estimate creatinine clearance CockcroftGault equation &lt; 60 ml/min , contrast dye allergy , contraindication betablockers ( e.g . severe asthma , hypotension , heart block ) , contraindication nitroglycerin ( e.g . continuous administration phosphodiesterase inhibitor ) , body weight great 320 lbs PET scanner table limitation ) report subject significant radiation exposure course year prior enrollment ; significant exposure define : 2 myocardial perfusion study within past 12 month 2 CT angiogram within past 12 month concurrent enrollment clinical trial judge investigator introduce concern safety confound</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>psoriasis</keyword>
	<keyword>cardiovascular disease risk</keyword>
	<keyword>atherosclerosis</keyword>
	<keyword>etanercept ( enbrel )</keyword>
</DOC>